Dr Robin Knight, Co-Founder & Co-CEO of IN-PART, discusses the emerging importance of outsourcing ‘landscaping’ activities within the pharmaceuticals industry and the benefits of adopting an openly innovative approach that pools sources of innovation from a wide variety of areas.
In the dynamic world of biopharmaceuticals, where groundbreaking discoveries emerge at an unprecedented scale, larger, more established pharma companies are finding themselves in an unfamiliar and precarious position. As nimble biotech start-ups and university spinouts enter the market backed by significant investment and eye-popping financial rounds, big pharma’s competitive edge could be under threat.